Gain-of-function (GOF) p53 mutations are observed frequently in most intractable human cancers and establish dependency for tumor maintenance and progression. While some of the genes induced by GOF p53 have been implicated in more rapid cell proliferation compared with p53-null cancer cells, the mechanism for dependency of tumor growth on mutant p53 is unknown. This report reveals a therapeutically targetable mechanism for GOF p53 dependency. We have shown that GOF p53 increases DNA replication origin firing, stabilizes replication forks, and promotes micronuclei formation, thus facilitating the proliferation of cells with genomic abnormalities. In contrast, absence or depletion of GOF p53 leads to decreased origin firing and a higher frequency of fork collapse in isogenic cells, explaining their poorer proliferation rate. Following genome-wide analyses utilizing ChIP-Seq and RNA-Seq, GOF p53–induced origin firing, micronuclei formation, and fork protection were traced to the ability of GOF p53 to transactivate cyclin A and CHK1. Highlighting the therapeutic potential of CHK1’s role in GOF p53 dependency, experiments in cell culture and mouse xenografts demonstrated that inhibition of CHK1 selectively blocked proliferation of cells and tumors expressing GOF p53. Our data suggest the possibility that checkpoint inhibitors could efficiently and selectively target cancers expressing GOF p53 alleles.
Shilpa Singh, Catherine A. Vaughan, Rebecca A. Frum, Steven R. Grossman, Sumitra Deb, Swati Palit Deb
Title and authors | Publication | Year |
---|---|---|
The Role of p53 Mutations in Early and Late Response to Mitotic Aberrations
Hertel A, Storchová Z |
Biomolecules | 2025 |
Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy
Song B, Yang P, Zhang S |
2024 | |
Targeting mutant p53: a key player in breast cancer pathogenesis and beyond.
Qayoom H, Haq BU, Sofi S, Jan N, Jan A, Mir MA |
Cell communication and signaling : CCS | 2024 |
Oncogenic Mutant p53 Sensitizes Non-Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress-Dependent Induction of Mitochondrial Apoptosis.
Chougoni KK, Neely V, Ding B, Oduah E, Lam VT, Hu B, Koblinski JE, Windle BE, Palit Deb S, Deb S, Nieva JJ, Radhakrishnan SK, Harada H, Grossman SR |
Cancer research communications | 2024 |
From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy.
Ahmadi SE, Rahimian E, Rahimi S, Zarandi B, Bahraini M, Soleymani M, Safdari SM, Shabannezhad A, Jaafari N, Safa M |
Biomarker research | 2024 |
Rewired m(6)A epitranscriptomic networks link mutant p53 to neoplastic transformation.
Xu A, Liu M, Huang MF, Zhang Y, Hu R, Gingold JA, Liu Y, Zhu D, Chien CS, Wang WC, Liao Z, Yuan F, Hsu CW, Tu J, Yu Y, Rosen T, Xiong F, Jia P, Yang YP, Bazer DA, Chen YW, Li W, Huff CD, Zhu JJ, Aguilo F, Chiou SH, Boles NC, Lai CC, Hung MC, Zhao Z, Van Nostrand EL, Zhao R, Lee DF |
Nature Communications | 2023 |
Reactivation of mutant p53 in esophageal squamous cell carcinoma by isothiocyanate inhibits tumor growth
Guan L, Yang Y, Lu Y, Chen Y, Luo X, Xin D, Meng X, Shan Z, Jiang G, Wang F |
Frontiers in pharmacology | 2023 |
Gain-of-Function Variomics and Multi-omics Network Biology for Precision Medicine.
Li MM, Awasthi S, Ghosh S, Bisht D, Coban Akdemir ZH, Sheynkman GM, Sahni N, Yi SS |
Methods in molecular biology (Clifton, N.J.) | 2023 |
Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients
O Hassin, N Nataraj, M Shreberk-Shaked, Y Aylon, R Yaeger, G Fontemaggi, S Mukherjee, M Maddalena, A Avioz, O Iancu, G Mallel, A Gershoni, I Grosheva, E Feldmesser, S Ben-Dor, O Golani, A Hendel, G Blandino, D Kelsen, Y Yarden, M Oren |
Nature Communications | 2022 |
Disrupted control of origin activation compromises genome integrity upon destabilization of Polε and dysfunction of the TRP53-CDKN1A/P21 axis
Borel V, Boeing S, Van Wietmarschen N, Sridharan S, Hill BR, Ombrato L, Perez-Lloret J, Jackson D, Goldstone R, Boulton SJ, Nussenzweig A, Bellelli R |
Cell Reports | 2022 |
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation.
Chen X, Zhang T, Su W, Dou Z, Zhao D, Jin X, Lei H, Wang J, Xie X, Cheng B, Li Q, Zhang H, Di C |
Cell Death and Disease | 2022 |
The oncogenicity of tumor-derived mutant p53 is enhanced by the recruitment of PLK3
CA Vaughan, S Singh, MA Subler, JJ Windle, K Inoue, EA Fry, R Pillappa, SR Grossman, B Windle, WA Yeudall, SP Deb, S Deb |
Nature Communications | 2021 |
Replication stress promotes cell elimination by extrusion
VK Dwivedi, C Pardo-, R Droste, JN Kong, N Tucker, DP Denning, J Rosenblatt, HR Horvitz |
Nature | 2021 |
Oligomerization of Mutant p53 R273H is not Required for Gain-of-Function Chromatin Associated Activities
GK Annor, N Elshabassy, D Lundine, DG Conde, G Xiao, V Ellison, J Bargonetti |
Frontiers in Cell and Developmental Biology | 2021 |
Mutant p53 in Cancer Progression and Targeted Therapies
G Zhu, C Pan, JX Bei, B Li, C Liang, Y Xu, X Fu |
Frontiers in Oncology | 2020 |
Chaperones and Ubiquitin Ligases Balance Mutant p53 Protein Stability in Esophageal and Other Digestive Cancers
MS Martinho, DJ Nancarrow, TS Lawrence, DG Beer, D Ray |
CMGH Cellular and Molecular Gastroenterology and Hepatology | 2020 |
Gain-of-function mutant p53 in cancer progression and therapy
C Zhang, J Liu, D Xu, T Zhang, W Hu, Z Feng |
Journal of Molecular Cell Biology | 2020 |
DNA replication in progenitor cells and epithelial regeneration after lung injury requires the oncoprotein MDM2
Shilpa Singh, Catherine Vaughan, Christopher Rabender, Ross Mikkelsen, Sumitra Deb, Swati Palit Deb |
JCI Insight | 2019 |
Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis
Y Stein, V Rotter, R Aloni-Grinstein |
International journal of molecular sciences | 2019 |
Molecular crosstalk between cancer and neurodegenerative diseases
J Seo, M Park |
Cellular and Molecular Life Sciences | 2019 |
The anticancer effects of cinobufagin on hepatocellular carcinoma Huh‑7�cells are associated with activation of the p73 signaling pathway
L Zhao, L Fu, Z Xu, R Fan, R Xu, R Fu, S Zou, C Wang, Y Zhang, J Wang, J Bao, Z Wang, X Hou, Y Zheng, E Dai, F Wang |
Molecular medicine reports | 2019 |
Genome-Wide Small RNA Sequencing Identifies MicroRNAs Deregulated in Non-Small Cell Lung Carcinoma Harboring Gain-of-Function Mutant p53
A Datta, P Das, S Dey, S Ghuwalewala, D Ghatak, SK Alam, R Chatterjee, S Roychoudhury |
Genes & development | 2019 |
Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer
G Xiao, D Lundine, GK Annor, J Canar, V Ellison, A Polotskaia, PL Donabedian, T Reiner, GF Khramtsova, OI Olopade, A Mazo, J Bargonetti |
Cancer research | 2019 |
DNA Repair: Methods and Protocols
L Balakrishnan, J Stewart |
2019 | |
Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target
R Schulz-Heddergott, U Moll |
Cancers | 2018 |
Genomic instability in mutant p53 cancer cells upon entotic engulfment
HL Mackay, D Moore, C Hall, NJ Birkbak, M Jamal-Hanjani, SA Karim, VM Phatak, L Piñon, JP Morton, C Swanton, JL Quesne, PA Muller |
Nature Communications | 2018 |
Mutant p53 as a guardian of the cancer cell
F Mantovani, L Collavin, GD Sal |
Cell Death and Differentiation | 2018 |
The Tip of an Iceberg: Replication-Associated Functions of the Tumor Suppressor p53
V Gottifredi, L Wiesmüller |
Cancers | 2018 |